The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients

Autor:	Daniela Alexandru-Abrams, Michelle Paff, Daniela A. Bota, Frank P.K. Hsu
Jazyk:	angličtina
Rok vydání:	2014
Předmět:	Oncology KPS Epidemiology medicine.medical_treatment delayed-type hypersensitivity Review year EGFRVIII WHO Mice day Antineoplastic Combined Chemotherapy Protocols Cancer transforming growth factor beta Surveillance Brain Neoplasms Vaccination OS DTH major histocompatibility complex HLA Bevacizumab ErbB Receptors GAGE IL-12 5.1 Pharmaceuticals Medical Microbiology IL-10 Immunotherapy Development of treatments and therapeutic interventions National Cancer Institute of Canada medicine.medical_specialty Subunit TTP Dacarbazine Immunology Brain tumor World Health Organization Irinotecan GBM antigen-presenting cell Disease-Free Survival Ab human leukocyte antigen Grb2 Humans Progression-free survival CD25 Pharmacology Granulocyte-macrophage colony-stimulating factor prostaglandin E2 Epidermal Growth Factor glioblastoma A Complementary Trial of an Immunotherapy Vaccine against Tumor Specific EGRFvIII medicine.disease CD4 NCIC APC Cytotoxic T lymphocytes SEER TGF-b Brain Cancer Camptosar CTL Growth factor receptor-bound protein 2 rat sarcoma genes KLH MHC TMZ Glioblastoma BBB progression-free survival Treg cells Ras blood brain barrier temozolomide time to progression regulatory T cells PFS antibody CPT-11 vaccine Monoclonal Immunology and Allergy Humanized ACTIVATE Interferon gamma Vaccines G antigen gene family lipopolysaccharide Pharmacology and Pharmaceutical Sciences Chemoradiotherapy Interleukin-12 VEGF Interleukin-10 EORTC Blood-Brain Barrier 6.1 Pharmaceuticals Vaccines Subunit European Organization for Research and Treatment of Cancer PGE2 CNS MGMT medicine.drug Receptor LPS keyhole limpet hemocyanin overall survival brain therapies Biology Karnofsky performance status Antibodies Monoclonal Humanized cluster of differentiation 4 Cancer Vaccines Antibodies Immune system Rare Diseases Internal medicine and End Results Program Virology cluster of differentiation 25 medicine Temozolomide Animals O-6-methylguanine-DNA methyltransferase T helper type 2 cells IL-2 INF-g Neurosciences Evaluation of treatments and therapeutic interventions GM-CSF central nervous system Brain Disorders Orphan Drug TH2 cells Interleukin-2 Immunization Camptothecin Vascular endothelial growth factor The epidermal growth factor receptor variant III Glioblastoma Multiforme
Zdroj:	Paff, M; Alexandru-Abrams, D; Hsu, FPK; & Bota, DA. (2014). The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients. Human Vaccines and Immunotherapeutics, 10(11), 3322-3331. doi: 10.4161/21645515.2014.983002. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/8194m480 Human vaccines & immunotherapeutics, vol 10, iss 11
DOI:	10.4161/21645515.2014.983002.
Popis:	© 2014 Taylor & Francis Group, LLC. Glioblastoma Multiforme (GBM) is the most common type of brain tumor and it is uniformly fatal. The community standard of treatment for this disease is gross or subtotal resection of the tumor, followed by radiation and temozolomide. At recurrence bevacizumab can be added for increased progression free survival. Many challenges are encountered while trying to devise new drugs to treat GBM, such as the presence of the blood brain barrier which is impermeable to most drugs. Therefore in the past few years attention was turned to immunological means for the treatment of this devastating disease. EGFRvIII targeting has proven a good way to attack glioblastoma cells by using the immune system. Although in still in development, this approach holds the promise as a great first step toward immune-tailored drugs for the treatment of brain cancers.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d945baa63df0302cde24daabd8a7bb1d http://www.escholarship.org/uc/item/8194m480 Zobrazit plný text záznamu